MACS GMP Recombinant Human IL-2

MACS GMP Recombinant Human IL-2

Interleukin 2 (IL-2), a potent lymphoid cell growth factor, plays an important role in both the activation and maintenance of immune responses and in lymphocyte development. IL-2 promotes, for instance, proliferation and differentiation of T cells, NK cells, and B cells.
MACS GMP Recombinant Human IL-2 is designed for
ex vivo
cell culture processing. No animal- or human-derived materials were used for the manufacture of this product, unless otherwise stated in the respective Certificate of Origin. The product is lyophilized without carrier protein or preservatives.


MACS GMP Products are for research use and
ex vivo
cell culture processing only, and are not intended for human
in vivo
applications. For regulatory status in the USA, please contact your local representative.

Background information

IL-2 is a typical four α-helix bundle cytokine and is produced by activated T cells, especially the CD4
T helper cell population. IL-2 signals through a receptor complex consisting of IL-2 receptor α-chain (CD25), β-chain, and common γ-chain.


MACS GMP Recombinant Human IL-2 can be used for a variety of applications, including the
ex vivo
activation and expansion of T cells, e.g., antigen-specific cytotoxic T lymphocytes
or regulatory T cells
or the
ex vivo
stimulation of NK cells

Quality statement

MACS GMP Products are manufactured and tested under a quality management system (ISO 13485) and are in compliance with relevant GMP guidelines. They are designed following the recommendations of USP <1043> on ancillary materials.

Biological activity

  • The specific activity is determined by proliferation assay according to Gearing and Bird
    using CTLL-2 cells. The proliferation assay was calibrated with the 2nd international standard for human IL-2 (NIBSC code 86/500) provided by the National Institute for Biological Standards and Control.
  • Specific activity: ≥ 1×
  • Selected references

    1. Gearing, A. J. H. and Bird, C. B. (1987) Lymphokines and interferons, a practical approach. Oxford: IRL Press : 295
    2. Zhang, H. et al. (2007) 4-1BB is superior to CD28 costimulation for generating CD8+ cytotoxic lymphocytes for adoptive immunotherapy. J. Immunol. 179: 4910-4918
    3. Hinrichs et al. (2008)
      IL-2 and IL-21 confer opposing differentiation programs to CD8
      T cells for adoptive immunotherapy.
      Blood 111: 5326-5333
    4. Peters, J. H. et al. (2008)
      Ex vivo
      generation of human alloantigen-specific regulatory T cells from CD4
      T cells for immunotherapy.
      PLoS One 3(5): e2233
    5. Berg et al. (2009)
      ex vivo
      -expanded human natural killer cells up-regulate activating receptors and death receptor ligands and have enhanced cytolytic activity against tumor cells.
      Cytotherapy 11: 341-355
    6. McKenna, D. H. Jr. et al. (2007) Good manufacturing practices production of natural killer cells for immunotherapy: a six-year single-institution experience. Transfusion 47(3): 520-528
  • Brochures and posters

  • Certificates

    Please follow this
    to search for Certificates of Analysis (CoA) by lot number.
Product options: 3
E. coli
25 µg
EUR 190,00 
E. coli
100 µg
EUR 480,00 
E. coli
500 µg
EUR 1.620,00